New Breast Cancer Drug Shrinks Tumors or Slows Growth in Up to Half of Women
A new and experimental breast cancer drug called lapatinib inhibited tumor growth in nearly half of women who took it for eight weeks in a national Phase I clinical trial, according to results of a study being presented at the annual American Society of Clinical Oncology meeting in New Orleans.
Kimberly Blackwell, M.D., assistant professor of medicine, Duke University Medical Center
CREDIT: Duke University Medical Center
Kimberly Blackwell, M.D., an oncologist from the Duke Comprehensive Cancer Center, presented data showing that 46 percent of breast cancer patients who took the oral drug for eight weeks had stable disease or tumor shrinkage. Approximately 24 percent of patients who took the drug for four months had stable disease or tumor shrinkage.
The results are quite encouraging, said Blackwell, because lapatinib is one of the first drugs to elicit a response in women whose tumors did not respond to at least two traditional therapies, including trastuzumab (Herceptin).
Trastuzumab is the front-line drug used to treat women whose tumors overproduce a growth-regulating protein called Her-2. Trastuzumab blocks the Her-2 receptor on cancer cells and inhibits its signaling, thereby shrinking or stabilizing the tumor.
But nearly one-third of tumors with Her-2 over-expression do not respond to trastuzumab, said Blackwell. In the current trial, the majority of patients -- 59 percent -- had progressed through three, four or five traditional cancer drugs.
Lapatinib represents a new type of therapy because it targets Her-2 plus another growth factor protein called Epidermal Growth Factor (EGFR). "Blocking the action of two growth factors has a more profound effect on inhibiting cell growth than blocking a single growth factor, and we think this dual action on breast cancer cells is responsible for the positive effects were seeing," said Blackwell. The study was funded by GlaxoSmithKline, the maker of lapatinib.
The study showed that lapatinib was safe and had minimal side effects, because it targets only these two very specific receptor sites on breast cancer cells, said Blackwell. Five percent of women experienced a rash, 5 percent had fatigue, and 10 percent had diarrhea. In contrast, chemotherapy can cause debilitating nausea, anemia, fatigue and the potential for heart and liver damage.
The trial is continuing to recruit patients at Duke and other sites around the country.
Becky Levine | dukemed news
The most recent press releases about innovation >>>
Die letzten 5 Focus-News des innovations-reports im Überblick:
Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.
As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...
Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.
Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...
For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.
While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...
An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.
The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...
A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.
Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...